AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
Dermatomyositis‐associated interstitial lung disease (DM‐ILD) represents a severe and insidious complication of dermatomyositis (DM). The study aimed to investigate the association between DM‐ILD and arterial blood gas indices, serum ion levels, and the timing of interstitial lung disease onset, with the goal of identifying potential predictors for DM‐ILD.
The investigation involved the collection of basic data from 89 patients with DM hospitalized at the Chinese PLA General Hospital between January 2019 and April 2022, and 43 normal control patients hospitalized for physical examinations during the same period. Analyses were conducted to explore the relationship between DM‐ILD, arterial blood gas indices, disease duration, and serum ions. A regression model to predict DM‐ILD was developed using these indices, and a receiver operating characteristic curve was generated.
Significant differences were observed in pH and PaO2 between the control group and the disease group (p < 0.05). The DM group exhibited higher levels of pH, actual bicarbonate, and base excess (BE) compared with the control group. In contrast, pH and BE levels were lower in the DM‐ILD group than in the DM group, with these differences being statistically significant (p < 0.05). Interstitial lung disease was correlated with the duration of the disease and pH levels (p < 0.05). The cutoff values for age, disease duration, pH, and Cl− were 55.5 years, 5.5 years, 7.432, and 101.5 mmol/L, respectively. The model demonstrated a prediction sensitivity and specificity for DM‐ILD of 0.809 and 0.722, respectively, with an area under the curve of 0.809.
Arterial blood gas analysis and serum Cl− levels may assist in predicting DM‐ILD. A combined monitoring approach involving arterial blood gas pH, disease duration, age, and serum Cl− levels could enhance the accuracy of DM‐ILD predictions and hold significant clinical evaluation potential.
Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti‐MDA5 antibody: study of 121 cases. Neurology. 2020;95(1):e70–8. https://doi.org/10.1212/WNL.0000000000009727
Romero‐Bueno F, Diaz Del Campo P, Trallero‐Araguás E, Ruiz‐Rodríguez JC, Castellvi I, Rodriguez‐Nieto MJ, et al. Recommendations for the treatment of anti‐melanoma differentiation‐associated gene 5‐positive dermatomyositis‐associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020;50(4):776–90. https://doi.org/10.1016/j.semarthrit.2020.03.007
Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–53. https://doi.org/10.1007/s40257-020-00502-6
DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267–81. https://doi.org/10.1016/j.jaad.2019.06.1309
Sun KY, Fan Y, Wang YX, Zhong YJ, Wang GF. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta‐analysis from 2000 to 2020. Semin Arthritis Rheum. 2021;51(1):175–91. https://doi.org/10.1016/j.semarthrit.2020.11.009
Respiratory Council of Chinese Research Hospital Association. Chinese expert‐based consensus statement on diagnosis and treatment of idiopathic inflammatory myopathy associated interstitial lung disease. Chin J Tuberc Respir Dis. 2022;45(7):635–50. https://doi.org/10.3760/cma.j.cn112147-20220108-00025
Vojinovic T, Cavazzana I, Ceruti P, Fredi M, Modina D, Berlendis M, et al. Predictive features and clinical presentation of interstitial lung disease in inflammatory Myositis. Clin Rev Allergy Immunol. 2021;60(1):87–94. https://doi.org/10.1007/s12016-020-08814-5
Long K, Danoff SK. Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med. 2019;40(3):561–72. https://doi.org/10.1016/j.ccm.2019.05.004
Barba T, Fort R, Cottin V, Provencher S, Durieu I, Jardel S, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta‐analysis. Autoimmun Rev. 2019;18(2):113–22. https://doi.org/10.1016/j.autrev.2018.07.013
Xu L, Wang F, Luo F. Rituximab for the treatment of connective tissue disease‐associated interstitial lung disease: a systematic review and meta‐analysis. Front Pharmacol. 2022;13:1019915. https://doi.org/10.3389/fphar.2022.1019915
Carlino MV, Guarino M, Izzo A, Carbone D, Arnone MI, Mancusi C, et al. Arterial blood gas analysis utility in predicting lung injury in blunt chest trauma. Respir Physiol Neurobiol. 2020;274:103363. https://doi.org/10.1016/j.resp.2019.103363
Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10‐12 October 2003,Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337–45. https://doi.org/10.1016/j.nmd.2004.02.006
Leung AKC, Lam JM, Alobaida S, Leong KF, Wong AHC. Juvenile dermatomyositis: advances in pathogenesis, assessment, and management. Curr Pediatr Rev. 2021;17(4):273–87. https://doi.org/10.2174/1573396317666210426105045
Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: current concepts. Clin Dermatol. 2018;36(4):450–8. https://doi.org/10.1016/j.clindermatol.2018.04.003
Sugiyama Y, Yoshimi R, Tamura M, Takeno M, Kunishita Y, Kishimoto D, et al. The predictive prognostic factors for polymyositis/dermatomyositis‐associated interstitial lung disease. Arthritis Res Ther. 2018;20(1):7. https://doi.org/10.1186/s13075-017-1506-7
Fidkowski C, Helstrom J. Diagnosing metabolic acidosis in the critically ill: bridging the anion gap, Stewart, and base excess methods. J Can Anaesth. 2009;56(3):247–56. https://doi.org/10.1007/s12630-008-9037-y
Davis MD, Walsh BK, Sittig SE, Restrepo RD. AARC clinical practice guideline: blood gas analysis and hemoximetry: 2013. Respir Care. 2013;58(10):1694–703. https://doi.org/10.4187/respcare.02786
Buzan MTA, Pop CM. State of the art in the diagnosis and management of interstitial lung disease. Clujul Med. 2015;88(2):116–23. https://doi.org/10.15386/cjmed-457
Zhan X, Yan W, Wang Y, Li Q, Shi X, Gao Y, et al. Clinical features of anti‐synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. BMC Pulm Med. 2021;21(1):57. https://doi.org/10.1186/s12890-021-01399-5
Schulte JJ, Husain AN. Connective tissue disease related interstitial lung disease. Surg Pathol Clin. 2020;13(1):165–88. https://doi.org/10.1016/j.path.2019.11.005
Wang J, Zhang W, Wu L, Mei Y, Cui S, Feng Z, et al. New insights into the pathophysiological mechanisms underlying cardiorenal syndrome. Aging. 2020;12(12):12422–31. https://doi.org/10.18632/aging.103354
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
京公网安备11010802044758号